Sign in
Taking peoplePhase 2/3

The Use of Melatonin for Delirium Prevention in Medically Hospitalized Patients

Key facts

Who runs it
Sultan Qaboos University
Where
Oman1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2/3
People taking part
240 people, planned
Started
30 Sept 2024
Planned end
Jun 2025
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Intervention 1
  • Intervention 2
  • Control
Record updated
14 January 2025

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patient aged 65 years and above acutely admitted under the care of General Internal Medicine Unit

Who cannot take part

  • If enteral medications are not allowed due to unavailability of nasogastric tube
  • Patient on strong cytochrome P450 1A2 (CYP1A2) inhibitors (namely: fluvoxamine and viloxazine)
  • If enteral medications are contraindicated due to gastrointestinal conditions
  • Patient with active alcohol drinking or admitted with alcohol withdrawal syndrome
  • Patients with the following autoimmune diseases (Rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus)
  • Allergy to melatonin
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (liver function tests) > 3 times the upper limit of normal
  • Patients admitted to the ward, however meeting requirement for vasopressors or non-invasive ventilation
  • Patient admitted through emergency to Intensive Care Unit (ICU) or High Dependency Unit (HDU)
  • Aphasic patients
  • Patients with language barriers
  • Already taking melatonin or ramelteon at the time of randomization
  • Presence of delirium at the time of randomization
  • Subject or proxy unable to provide informed consent within 24 hours of admission

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The high prevalence of delirium in hospitalized older adults, with significant associated morbidity and mortality, emphasize the need for effective prevention strategies. Limited trials have explored melatonin's potential in preventing delirium among patients admitted to general medical wards. Previous trials on melatonin's preventive role in medical wards had limitations, necessitating a robust, double-blinded, placebo-controlled design with a larger sample size. This randomized, double-blind study of melatonin versus placebo aims to investigate the efficacy of melatonin, a neurohormone regulating the sleep-wake cycle, in preventing delirium among medically hospitalized patients aged 65 or older. Given the high prevalence of delirium in this population and its association with adverse outcomes, the study seeks to contribute valuable insights into an effective preventive strategy.

The 3 groups in the trial

  • Melatonin 5mg/dayTreatment being tested

    Intervention group 1: Melatonin 5mg/day * Study drug will be given at 20:00 - 22:00 daily, starting on the day of enrolment until discharge, death, or up to 5 days as most medically hospitalised patients at great risk of delirium in the first few days of admission.(20) * The study medication will be given by mouth or if needed, via the feeding tube followed by a flush with 20mL water.

    Treatment: Intervention 1

  • Melatonin 8 mg/dayTreatment being tested

    Intervention group 2:Study drug will be given at 20:00 - 22:00 daily, starting on the day of enrolment until discharge, death, or up to 5 days as most medically hospitalised patients at great risk of delirium in the first few days of admission.(20) • The study medication will be given by mouth or if needed, via the feeding tube followed by a flush with 20mL water.

    Treatment: Intervention 2

  • PlaceboPlacebo, for comparison

    * Study drug will be given at 20:00 - 22:00 daily, starting on the day of enrolment until discharge, death, or up to 5 days as most medically hospitalised patients at great risk of delirium in the first few days of admission. (20) * The study medication will be given by mouth or if needed, via the feeding tube followed by a flush with 20mL water.

    Treatment: Control

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Melatonin Versus Placebo for Prevention of Delirium Among Medically Hospitalized Patients: Study Protocol for a Single-Center, Double-Blinded, Randomised Controlled Trial
Publications
Record updated
14 January 2025